White House Announces New Loyalty Points for FDA Candidates
In a stunningly innovative initiative, the White House has declared the introduction of a loyalty points system for candidates vying for the FDA leadership. This groundbreaking program aims to ensure that only the most loyal and strategically compliant individuals are appointed to key positions, especially as the mid-terms loom ominously on the horizon. In a memo circulated to potential nominees, the administration emphasized that loyalty points will be awarded based on criteria such as public endorsements, social media shout-outs, and the ability to parrot administration talking points with precision.
"Weβre not just looking for qualified candidates anymore; we want loyal foot soldiers ready to march in lockstep with our agenda," said an anonymous source within the administration. This bold strategy comes as a response to past criticisms regarding the FDA's independence, a notion the administration has decided to redefine as an obstacle to effective governance. Why let science and public health stand in the way of a well-orchestrated political campaign?
Still Beats Watergate:
Sponsor success. Continue reading:
Sources close to the White House have indicated that loyalty points can be accrued through various means, including attendance at exclusive donor events, participation in grassroots campaigns, and, more importantly, demonstrating unwavering support for the administration’s policies, regardless of their impact on public health. In a press briefing, when asked how this system would affect the FDA’s scientific integrity, the spokesperson replied, "Integrity is overrated when you're trying to win elections. We need warriors, not scientists."
As part of this new regime, applicants for the FDA leadership will be required to undergo a rigorous vetting process that includes a thorough examination of their social media activity and a public loyalty pledge. This pledge will require candidates to promise not only to support the current administration's health policies but also to actively discredit any scientific findings that contradict the party line. In other words, the new FDA will focus on manufacturing consent rather than ensuring safe and effective health solutions.
Critics of the initiative have echoed concerns that this could lead to catastrophic public health decisions made in the name of political expediency. However, supporters argue that the priority should be on securing votes, not on the trivialities of evidence-based practice. After all, public health is merely a means to an end in the grand theater of politics.
In a final twist of irony, the White House plans to host a gala event to celebrate the successful launch of this initiative, complete with a loyalty points leaderboard displayed prominently for all to see. The gala will feature prizes for top performers, including exclusive access to the Oval Office and the opportunity to sign a ceremonial document proclaiming allegiance to the administration's health agenda. As the mid-terms approach, it’s clear that loyalty is the new currency in Washington, and the administration is ready to spend it lavishly.





